Brukinsa - (80 mg ; Capsule)

Generic Name	Zanubrutinib	**Innovator**	Beigene
Dosage	80 mg ; Capsule	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: ? Mantle cell lymphoma (MCL) who have received at least one prior therapy. ? Waldenström's macroglobulinemia (WM). ? Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Brukinsa - (160 mg ; Tablets)

Generic Name	Zanubrutinib	**Innovator**	BeOne Medicines USA Inc.
Dosage	160 mg ; Tablets	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	None		
Complexities	No		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.